The protocol encouraged, but did not
mandate, the use of drug classes with the strongest
evidence for reduction in cardiovascular
outcomes, including thiazide-type diuretics (encouraged
as the first-line agent), loop diuretics
(for participants with advanced chronic kidney
disease), and beta-adrenergic blockers (for those
with coronary artery disease).5,27 Chlorthalidone
was encouraged as the primary thiazide-type diuretic,
and amlodipine as the preferred calciumchannel
blocker
The protocol encouraged, but did notmandate, the use of drug classes with the strongestevidence for reduction in cardiovascularoutcomes, including thiazide-type diuretics (encouragedas the first-line agent), loop diuretics(for participants with advanced chronic kidneydisease), and beta-adrenergic blockers (for thosewith coronary artery disease).5,27 Chlorthalidonewas encouraged as the primary thiazide-type diuretic,and amlodipine as the preferred calciumchannelblocker
การแปล กรุณารอสักครู่..